DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts" report to their offering.

MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts

Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to the increased life span and increasing adoption of Western lifestyle risk factors. Predictive breast cancer gene tests can be used to identify women who are at increased risk of developing hereditary breast cancer. The Predictive Breast Cancer Gene Testing market has seen exponential growth in the US, dominated by Myriad Genetics. Gene testing in Europe is mostly carried out by the state funded health sector, but increasingly private companies are offering breast cancer gene tests to physicians. Myriad Genetics' position in the market is dependent on it being the leading provider of the most common breast cancer mutations. By the end of our forecast period, the competitive landscape will experience significant change due to the erosion of Myriad Genetics' position, as a result of the expiry of key patents, and the emergence of alternative molecular technologies.

Scope

- An overview of Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized EU Breast Cancer Gene Testing market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.

- Investigation of current and future market competition for Breast Cancer Gene Testing

- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.

- Competitor assessment including device approval analysis and device sales forecasts.

See original here:
Research and Markets: MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts

Comments are closed.